Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

jfun1 Apr. 27 at 7:39 PM

$BCTX 30 million mkt cap. Crazy if their drug works. Worth a swing imo

0 · Reply

SmallCapGrowth Apr. 27 at 5:10 PM

BB's Stock Haven : NASDAQ News Alert: $BCTX to showcase six... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177543542 via @Investors_Hub

0 · Reply

laaarsas Apr. 27 at 5:00 PM

$BCTX What is this donkey case?

0 · Reply

laaarsas Apr. 27 at 4:54 PM

$BCTX Wassup donkeys?

0 · Reply

SmallCapGrowth Apr. 27 at 4:34 PM

NASDAQ News Alert: $BCTX to showcase six clinical data presentations at ASCO 2026 - survival and quality of life data plus biomarker analyses from its ongoing Phase 3 study. A major catalyst to watch as the company advances. NEWS: https://globenewswire.com/news-release/2026/04/27/3281510/0/en/briacell-announces-six-clinical-data-presentations-at-asco-2026.html

0 · Reply

SmallCapGrowth Apr. 27 at 4:32 PM

0 · Reply

SmallCapGrowth Apr. 27 at 3:21 PM

0 · Reply

ZacksResearch Apr. 27 at 2:49 PM

$BCTX gearing up for a major ASCO spotlight — is this the next biotech catalyst? 👀 BriaCell just announced 3 clinical poster presentations + 3 publication-only abstracts at the 2026 ASCO Annual Meeting, highlighting Bria-IMT + CPI data, survival outcomes, and ongoing Phase 3 biomarker analysis in metastatic breast cancer — with full details dropping May 21. Big-stage exposure + upcoming data visibility could put this name on traders’ radar fast. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/BCTX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-37913&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_37913

0 · Reply

SmallCapGrowth Apr. 27 at 1:54 PM

BriaCell Therapeutics Corp ( $BCTX ): $BCTX to showcase six clinical data pres... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177542406 via @Investors_Hub

0 · Reply

JediGreen Apr. 27 at 1:52 PM

$BCTX The way it’s worded at the end of this PR . Abstract Title: Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis. Session Type/Title: Poster Session - Developmental Therapeutics—Immunotherapy Poster Board: 442 Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT

2 · Reply

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

2026-04-21T13:28:43.000Z - 6 days ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

Tue, 21 Apr 2026 07:30:00 -0400 - 6 days ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

2026-04-20T13:32:04.000Z - 7 days ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

Mon, 20 Apr 2026 07:30:00 -0400 - 7 days ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 27 days ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 5 weeks ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

Wed, 18 Mar 2026 07:30:00 -0400 - 5 weeks ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 6 weeks ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 7 weeks ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 2 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

Wed, 18 Feb 2026 17:30:00 -0500 - 2 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Tue, 17 Feb 2026 07:30:00 -0500 - 2 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T13:30:56.000Z - 3 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

Wed, 28 Jan 2026 07:30:00 -0500 - 3 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T13:32:37.000Z - 3 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

Tue, 27 Jan 2026 07:30:00 -0500 - 3 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

2026-01-19T16:00:45.000Z - 3 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-16T13:58:57.000Z - 3 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

Thu, 15 Jan 2026 16:05:00 -0500 - 3 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

2026-01-14T11:36:30.000Z - 3 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:19:44.000Z - 3 months ago

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

2026-01-14T10:55:53.000Z - 3 months ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T06:56:44.000Z - 3 months ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

Tue, 13 Jan 2026 21:00:00 -0500 - 3 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T20:32:32.000Z - 3 months ago

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

2026-01-13T14:08:02.000Z - 3 months ago

BriaCell Surge Above 50%; What's The Buzz?

2026-01-13T12:53:09.000Z - 3 months ago

BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial

Tue, 13 Jan 2026 07:30:00 -0500 - 3 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Thu, 18 Dec 2025 07:30:00 -0500 - 4 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

2025-12-10T13:29:00.000Z - 4 months ago

BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposium

Wed, 10 Dec 2025 07:30:00 -0500 - 4 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

2025-12-09T13:34:16.000Z - 4 months ago

BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Breast Cancer

Tue, 09 Dec 2025 07:30:00 -0500 - 4 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

2025-12-02T12:50:27.000Z - 5 months ago

BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 Symposium

Tue, 02 Dec 2025 07:30:00 -0500 - 5 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

2025-12-01T12:53:14.000Z - 5 months ago

Bicara Therapeutics (BCTX) Releases Promising Early Data from Cancer Drug Trial

Tue, 25 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

2025-11-20T13:28:07.000Z - 5 months ago

BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development

Thu, 20 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Tue, 18 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Fri, 07 Nov 2025 07:30:00 -0500 - 6 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Tue, 04 Nov 2025 07:30:00 -0500 - 6 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

2025-10-28T08:01:00.000Z - 6 months ago

Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding

2025-10-27T19:05:00.000Z - 6 months ago

Top 3 Earnings Acceleration Buys for November

2025-10-22T12:51:17.000Z - 6 months ago

BriaCell (BCTX) Receives Positive Safety Endorsement for Phase 3 Cancer Study

Wed, 22 Oct 2025 07:30:00 -0400 - 6 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2025-10-21T20:52:14.000Z - 6 months ago

BriaCell Rises On Phase 3 Expansion And MSK Collaboration

2025-10-21T13:25:38.000Z - 6 months ago

BriaCell (BCTX) Expands Phase 3 Cancer Study with New Major Centers

2025-10-21T12:50:54.000Z - 6 months ago

BriaCell (BCTX) Partners with MSK for Cancer Immunotherapy Development

Oct 21, 2025, 7:50 AM EDT - 6 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 6 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 6 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 7 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 7 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 8 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 8 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 8 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 9 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 9 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 9 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 9 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 9 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 10 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 10 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 10 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 10 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 10, 2025, 7:30 AM EDT - 10 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 9, 2025, 7:30 AM EDT - 10 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 8, 2025, 7:30 AM EDT - 10 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 2, 2025, 7:30 AM EDT - 10 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jun 24, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 4, 2025, 7:30 AM EDT - 11 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 2, 2025, 7:30 AM EDT - 11 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

May 27, 2025, 7:30 AM EDT - 11 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 23, 2025, 7:30 AM EDT - 1 year ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 20, 2025, 7:30 AM EDT - 1 year ago

BriaCell CEO Letter to Shareholders

jfun1 Apr. 27 at 7:39 PM

$BCTX 30 million mkt cap. Crazy if their drug works. Worth a swing imo

0 · Reply

SmallCapGrowth Apr. 27 at 5:10 PM

BB's Stock Haven : NASDAQ News Alert: $BCTX to showcase six... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177543542 via @Investors_Hub

0 · Reply

laaarsas Apr. 27 at 5:00 PM

$BCTX What is this donkey case?

0 · Reply

laaarsas Apr. 27 at 4:54 PM

$BCTX Wassup donkeys?

0 · Reply

SmallCapGrowth Apr. 27 at 4:34 PM

0 · Reply

SmallCapGrowth Apr. 27 at 4:32 PM

0 · Reply

SmallCapGrowth Apr. 27 at 3:21 PM

0 · Reply

ZacksResearch Apr. 27 at 2:49 PM

0 · Reply

SmallCapGrowth Apr. 27 at 1:54 PM

BriaCell Therapeutics Corp ( $BCTX ): $BCTX to showcase six clinical data pres... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177542406 via @Investors_Hub

0 · Reply

JediGreen Apr. 27 at 1:52 PM

2 · Reply

SmallCapGrowth Apr. 27 at 1:46 PM

$BCTX to showcase six clinical data presentations at ASCO 2026, including final randomized Phase 2 Bria-IMT survival and quality of life data plus biomarker analyses from its ongoing Phase 3 study. A major catalyst to watch as the company advances. https://globenewswire.com/news-release/2026/04/27/3281510/0/en/briacell-announces-six-clinical-data-presentations-at-asco-2026.html #Stocks #stockstobuy #stockstowatch #investors #BCTX @smallcapvoice

0 · Reply

MoeMaze Apr. 27 at 12:37 PM

$BCTX BCTX has officially invented a new market strategy: Good news = stock goes down. More good news = stock goes down faster. At this rate, please stop the updates before it reaches the Dead Sea scrolls. Amazing science, confusing chart.

1 · Reply

SmallCapVoice Apr. 27 at 11:34 AM

$BCTX is set to showcase six clinical data presentations at ASCO 2026, including final randomized Phase 2 Bria-IMT survival and quality of life data plus biomarker analyses from its ongoing Phase 3 study. A major catalyst to watch as the company advances. https://www.globenewswire.com/news-release/2026/04/27/3281510/0/en/briacell-announces-six-clinical-data-presentations-at-asco-2026.html

0 · Reply

JJBurch Apr. 27 at 8:31 AM

$OSRH 🚨 🚨 🚨 critical week where it breaks out. As of late March/April 2026, analysts have set a 12-month price target for OSR Holdings (OSRH) at $10.00, representing a potential massive upside from current levels near $0.60–$0.70. This bullish target is driven by potential milestone payments of up to $815 million from a licensing term sheet for VXM01 and global interest in their Woori IO non-invasive glucose monitor. Yahoo Finance Yahoo Finance +4 Average Target: $10.00 to $10.20 per share. $BCTX $IXHL $MITQ $PLTR

0 · Reply

JJBurch Apr. 27 at 8:24 AM

$OSRH $10+ price target for 2026 You do the math Congrats on finding this one Is a life changing opportunity $IXHL $MITQ $BCTX $PLTR

0 · Reply

JediGreen Apr. 27 at 12:46 AM

$BCTX

0 · Reply

JediGreen Apr. 27 at 12:46 AM

$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2854) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-02-12-11-00-00/index.html

0 · Reply

Rohtan Apr. 26 at 3:39 AM

$BCTX

0 · Reply

JediGreen Apr. 26 at 2:03 AM

$BCTX How much longer do you guys think until they release data? I don’t think they need 144 events to release data.

1 · Reply

FlareReboot47 Apr. 25 at 6:23 AM

$BCTX Asset Purchase Agreement (February/March 2026): BriaCell closed a transaction with BriaPro for an exclusive license to soluble CD80, expanding its immunotherapy toolkit

0 · Reply

BHWinehouse Apr. 24 at 6:41 PM

$BCTX -Phase 3 is already fully underway with imminent data -Strong survival signals in Phase 2 -Safety profile looks unusually clean -Quality of Life already holding up in Phase 3 -Nano cap

2 · Reply

MoeMaze Apr. 24 at 6:49 AM

$BCTX How can you buy a stock whose name literally says SELL? BriaCELL Therapeutics !!{. Maybe it’s time to switch to something with BUY …like Biotics. At least you won’t find Mr.Willy there ,BUY and Willy have issues , they Don’t click !

1 · Reply

Market Cap	28.13M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	111,284
Avg Vol	201,758
Day's Range	N/A - N/A
Shares Out	7.25M
Stochastic %K	18%
Beta	1.30
Analysts	Strong Buy
Price Target	$40.00